Browsing by Author Ledermann, Jonathan

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2017Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialGebski, Val; et al, Various; Huzarski, Tomasz; Korach, Jacob; Ledermann, Jonathan; Oza, Amit M; Penson, Richard; Pignata, Sandro; Poveda, Andres; Pujade-Lauraine, Eric; Selle, Frederic; NH&MRC Clinical Trials CentreOlaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, The Lancet Oncology, vol.18, 9, 2017,pp 1274-1284
2016Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerBoddy, Alan; Acton, Gary; Backholer, Zoe; Curtin, Nicola J; Drew, Yvette; Glasspool, Rosalind; Halford, Sarah; Hall, Geoff D.; Highley, Martin S.; Jamieson, David; Jayson, G. C.; Ledermann, Jonathan; Mangano, Raffaella; Murray, James; Plummer, Ruth; Rea, Daniel William; Sludden, Julieann; PharmacyPhase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer, British Journal of Cancer, vol.114, 7, 2016,pp 723-730
2011A phase 3 trial of bevacizumab in ovarian cancerBeale, Philip; Carey, Mark; Cervantes, Andres; Collinson, Fiona; du Bois, Andreas; Essapen, Sharadah; Gourley, Charlie; Kimmig, R; Kristensen, Gunnar; Kurzeder, Christian; Ledermann, Jonathan; Lemenin, Arto; Lortholary, Alain; Mirza, Mansoor Raza; Oza, Amit; Parmar, M. K. B.; Perren, Timothy; Pfisterer, J.; Plante, Marie; Pujade-Lauraine, Eric; Qian, Wendi; Sehouli, Jalid; Selle, Frederic; Stahle, Anne; Stark, Dan; Swart, Ann Marie; Central Clinical School: MedicineA phase 3 trial of bevacizumab in ovarian cancer, New England Journal of Medicine, vol.365, 26, 2011,pp 2484-2496
2014Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized studyHarnett, Paul; Bidziński, Mariusz; Blagden, Sarah; Del Prete, Salvatore; Fotopoulou, Christina; Gabra, Hani; Ghamande, Sharad; Gore, Martin; Green, John; Kaye, Stan; Ledermann, Jonathan; Mainwaring, Paul; Spaczyński, Marek; Vergote, Ignace; Vermorken, Jan; Western Clinical School: Medicine (Westmead)Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study, Annals of Oncology, vol.25, 1, 2014,pp 160-165
2014Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized studyHarnett, Paul; Bidziński, Mariusz; Blagden, Sarah; Del Prete, Salvatore; Fotopoulou, Christina; Gabra, Hani; Ghamande, Sharad; Gore, Martin; Green, John; Kaye, Stan; Ledermann, Jonathan; Mainwaring, Paul; Spaczyński, Marek; Vergote, Ignace; Vermorken, Jan; Western Clinical School: Medicine (Westmead)Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study, Annals of Oncology, vol.25, 1, 2014,pp 160-165